Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS: A Randomized, Placebo Controlled, Multicenter Trial

NCT04536350 is registered in ClinicalTrials.gov with Prof. Dr. Jörg Leuppi as lead sponsor.

NCT NCT04536350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04536350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS: A Randomized, Placebo Controlled, Multicenter Trial
Lead sponsor
Prof. Dr. Jörg Leuppi
Phase
Phase 2
Overall status
Terminated
Start date
May 18, 2021
Completion date
June 14, 2023
Enrollment
83 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ards, aviptadil, corona virus infection, covid19